

**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*

Docket Number (Optional)

RGT 7033

Application Number

10/757,343

Applicant(s)

Liszewicz, et al.

Filing Date

14 Jan 2004

Group Art Unit

1633**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
NK		6,420,176	7/16/02	Liszewicz and Lori			
NK		6,348,450	2/19/02	Tang et al.			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
NK		WO 99/43350	9/2/99	PCT				
NK		PCT/US02/16546	11/28/02	PCT				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

EXAMINER

/Nicole Kinsey/

DATE CONSIDERED

8/14/2006**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) RGT 7033		Application Number 10/757,343	
		Applicant(s) Liszewicz, et al.			
		Filing Date 14 Jan 2004		Group Art Unit 1633	

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>				
NK	Robinson, H. L. (2002). "New hope for an AIDS vaccine." <i>Nature Rev Immunol</i> 2(4): 239-50.				
	Fields, B. N. and D. M. Knipe, Eds. (1990). <i>Virology. Retroviridae and their replication</i> . New York, Raven Press, LTD				
	Chen, S. S., A. A. Ferrante, et al. (1996). "Characterization of an envelope mutant of HIV-1 that interferes with viral infectivity." <i>Virology</i> 226(2): 260-8				
	Smythe, J. A., D. Sun, et al. (1994). "A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection." <i>Proc Natl Acad Sci U S A</i> 91(9): 3657-61				
	Yung, E., M. Sorin, et al. (2001). "Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1." <i>Nat Med</i> 7(8): 920-6				
	Plavec, I., M. Agarwal, et al. (1997). "High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: implication for gene therapy of AIDS." <i>Gene Ther</i> 4(2): 128-39				
	Fraisier, C., D. A. Abraham, et al. (1998). "Inhibition of Tat-mediated transactivation and HIV replication with Tat mutant and repressor domain fusion proteins." <i>Gene Ther</i> 5(7): 946-54				
	Sawaya, B. E., K. Khalili, et al. (2000). "Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73." <i>J Virol</i> 74(10): 4877-81				
	Gitlin, S. D., P. F. Lindholm, et al. (1991). "Transdominant human T-cell lymphotropic virus type I TAX1 mutant that fails to localize to the nucleus." <i>J Virol</i> 65(5): 2612-21				
	Bohnelein, S., F. P. Pirker, et al. (1991). "Transdominant repressors for human T-cell leukemia virus type I rex and human immunodeficiency virus type 1 rev function." <i>J Virol</i> 65(1): 81-8				
	Smith, C. A. and N. A. DeLuca (1992). "Transdominant inhibition of herpes simplex virus growth in transgenic mice." <i>Virology</i> 191(2): 581-8				
NK	Chen, J., C. Panagiotidis, et al. (1992). "Multimerization of ICP0, a herpes simplex virus immediate-early protein." <i>J Virol</i> 66(9): 5598-602				

EXAMINER /Nicole Kinsey/	DATE CONSIDERED 8/14/2006
---------------------------------	----------------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) RGT 7033	Application Number 10/757,343
		Applicant(s) Lisiewicz, et al.	
		Filing Date 14 Jan 2004	Group Art Unit 1633

*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
NK	Piccinini, G., A. Folli, et al. (2002). "Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes." J Virol 76(5): 2274-8
	Jayan, G. C., P. Cordelier, et al. (2001). "SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional, and pol III promoters." Gene Ther 8(13): 1033-42
	Frankel, S. S., K. Tenner-Racz, et al. (1997). "Active replication of HIV-1 at the lymphoepithelial surface of the tonsil." Am J Pathol 151(1): 89-96
	Jamieson, B. D., G. M. Aldrovandi, et al. (1994). "Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity." J Virol 68(6): 3478-85
	Aldrovandi, G. M., L. Gao, et al. (1998). "Regions of human immunodeficiency virus type 1 nef required for function in vivo." J Virol 72(9): 7032-9
	Geffin, R., D. Wolf, et al. (2000). "Functional and structural defects in HIV type 1 nef genes derived from pediatric long-term survivors." AIDS Res Hum Retroviruses 16(17): 1855-68
	Lisiewicz, J., D. I. Gabrilovich, et al. (2001). "Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells." J Virol 75(16): 7621-8
	Zufferey, R., T. Dull, et al. (1998). "Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery." J Virol 72(12): 9873-80
	Vicenzi, E., D. S. Dimitrov, et al. (1994). "An integration-defective U5 deletion mutant of human immunodeficiency virus type 1 reverts by eliminating additional long terminal repeat sequences." J Virol 68(12): 7879-90
	Zhou, H., G. J. Rainey, et al. (2001). "Substrate sequence selection by retroviral integrase." J Virol 75(3): 1359-70
	Murphy, J. E. and S. P. Goff (1989) "Construction and analysis of deletion mutations in the U5 region of Moloney murine leukemia virus: effects on RNA packaging and reverse transcription." J Virol 63(1): 319-27
NK	Lisiewicz, J., E. Rosenberg, et al. (1999). "Control of HIV despite the discontinuation of antiretroviral therapy." N Engl J Med 340(21): 1683-4

EXAMINER <div style="text-align: center;">/Nicole Kinsey/</div>	DATE CONSIDERED <div style="text-align: center;">8/14/2006</div>
--------------------------------------------------------------------	---------------------------------------------------------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

RGT 7033

Application Number

10/757,343

Applicant(s)

Lisiewicz, et al.

Filing Date

14 Jan 2004

Group Art Unit

1633

*EXAMINER
INITIAL

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

NK

Lori, F., M. G. Lewis, et al. (2000). "Control of SIV rebound through structured treatment interruptions during early infection." Science 290(5496): 1591-3

Rosenberg, E. S., M. Altfeld, et al. (2000). "Immune control of HIV-1 after early treatment of acute infection." Nature 407(6803): 523-6

Barouch, D. H., J. Kunstman, et al. (2002). "Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes." Nature 415(6869): 335-9

Trono, D., M. B. Feinberg, et al. (1989). "HIV-1 gag mutants can dominantly interfere with the replication of the wild-type virus." Cell 59: 113-120

NK

Grant, E. P., M. T. Michalek, et al. (1995). "Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation." J Immunol 155(8): 3750-8

EXAMINER

/Nicole Kinsey/

DATE CONSIDERED

8/14/2006

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.